Subcutaneous · GLP-1 / glucagon dual
Pemvidutide
15 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
15
Active
2
Recruiting
1
Completed
10
Sites
158
Countries
3
Endpoints
89
Composite endpoints
10
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
7
Phase 1/2
4
Phase 2
4
Trials by status
Recruiting
1
Active, not recruiting
1
Completed
10
Terminated
2
Withdrawn
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
30
MASH / liver
16
Other clinical outcomes
12
Glycemic / diabetes
11
Cardiometabolic biomarkers
8
Weight & body composition
6
Other (unclassified)
3
Cardiovascular outcomes
2
Patient-reported / QoL
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
11
HbA1c, changeGlycemic
5
MRI-PDFF, % changeMASH
4
Body weight, absolute change (kg)Weight
3
CmaxSafety/PK
3
AUC₀–∞Safety/PK
2
All-cause deathCV
2
Immunogenicity (ADA)Safety/PK
2
Body weight, % changeWeight
2
Fasting glucose, changeGlycemic
2
HOMA-IR (insulin sensitivity)Glycemic
2
ELF score, changeMASH
2
Liver stiffness (VCTE), changeMASH
2
Total cholesterol, changeBiomarker
1
Serious AEs (any)Safety/PK
1
Plasma concentration (steady state)Safety/PK
1
Heart rate, changeBiomarker
1
MASH resolution, no fibrosis worseningMASH
1
Fibrosis ≥1-stage improvement, no MASH worseningMASH
1
MASH resolution + fibrosis improvementMASH
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
15 of 15